271 related articles for article (PubMed ID: 9442502)
1. Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance?
Sallerin-Caute B; Lazorthes Y; Deguine O; Francés B; Verdié JC; Charlet JP; Bastide R
Neurosurgery; 1998 Jan; 42(1):44-9; discussion 49-50. PubMed ID: 9442502
[TBL] [Abstract][Full Text] [Related]
2. Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer.
Gestin Y; Vainio A; Pégurier AM
Acta Anaesthesiol Scand; 1997 Jan; 41(1 Pt 1):12-7. PubMed ID: 9061109
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
[TBL] [Abstract][Full Text] [Related]
4. Spinal analgesia for severe cancer pain: A retrospective analysis of 60 patients.
Kiehelä L; Hamunen K; Heiskanen T
Scand J Pain; 2017 Jul; 16():140-145. PubMed ID: 28850391
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients.
van Dongen RT; Crul BJ; van Egmond J
Clin J Pain; 1999 Sep; 15(3):166-72. PubMed ID: 10524468
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer.
Gilmer-Hill HS; Boggan JE; Smith KA; Frey CF; Wagner FC; Hein LJ
Surg Neurol; 1999 Jan; 51(1):6-11. PubMed ID: 9952116
[TBL] [Abstract][Full Text] [Related]
7. Effect of intrathecal dexmedetomidine on spinal morphine analgesia in patients with refractory cancer pain.
Liu HJ; Gao XZ; Liu XM; Xia M; Li WY; Jin Y
J Palliat Med; 2014 Jul; 17(7):837-40. PubMed ID: 24702571
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain.
Anderson VC; Burchiel KJ
Neurosurgery; 1999 Feb; 44(2):289-300; discussion 300-1. PubMed ID: 9932882
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study.
Zheng S; He L; Yang X; Li X; Yang Z
Medicine (Baltimore); 2017 Mar; 96(11):e6354. PubMed ID: 28296770
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience.
Lin CP; Lin WY; Lin FS; Lee YS; Jeng CS; Sun WZ
J Formos Med Assoc; 2012 May; 111(5):253-7. PubMed ID: 22656395
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal and intraventricular morphine for pain in cancer patients: initial study.
Leavens ME; Hill CS; Cech DA; Weyland JB; Weston JS
J Neurosurg; 1982 Feb; 56(2):241-5. PubMed ID: 6172573
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.
Alicino I; Giglio M; Manca F; Bruno F; Puntillo F
Pain; 2012 Jan; 153(1):245-249. PubMed ID: 22082570
[TBL] [Abstract][Full Text] [Related]
13. Drug-related side effects of long-term intrathecal morphine therapy.
Ruan X
Pain Physician; 2007 Mar; 10(2):357-66. PubMed ID: 17387357
[TBL] [Abstract][Full Text] [Related]
14. Tolerance during long-term administration of intrathecal morphine.
Ali NM; Hoffman JS
Conn Med; 1989 May; 53(5):266-8. PubMed ID: 2736913
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain.
Yang CY; Wong CS; Chang JY; Ho ST
Can J Anaesth; 1996 Apr; 43(4):379-83. PubMed ID: 8697554
[TBL] [Abstract][Full Text] [Related]
16. An optimal dose study of intrathecal morphine in gynecological patients.
Rodanant O; Sirichotewithayakorn P; Sriprajittichai P; Charuluxananan S
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S331-7. PubMed ID: 12930007
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of "refractory" nonmalignant pain.
Nitescu P; Dahm P; Appelgren L; Curelaru I
Clin J Pain; 1998 Mar; 14(1):17-28. PubMed ID: 9535310
[TBL] [Abstract][Full Text] [Related]
18. Loss of intrathecal morphine analgesia in terminal cancer patients is associated with high levels of excitatory amino acids in the CSF.
Wong CS; Chang YC; Yeh CC; Huang GS; Cherng CH
Can J Anaesth; 2002; 49(6):561-5. PubMed ID: 12067866
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of severe cancer pain via spinal catheters].
Andersen JS; Markers PI; Valentin N
Ugeskr Laeger; 1996 Nov; 158(46):6613-6. PubMed ID: 8966828
[TBL] [Abstract][Full Text] [Related]
20. Low-dose intrathecal naloxone to enhance intrathecal morphine analgesia: a case report.
Hamann S; Sloan PA; Witt W
J Opioid Manag; 2008; 4(4):251-4. PubMed ID: 18837205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
